BeiKe Bio-Tech To Set Up Asia’s Largest Stem Cell Base
This article was originally published in PharmAsia News
Shenzhen Beike Bio-Tech has signed an agreement with the administrative commission of China Medical City to jointly establish Asia's largest stem cell base, which can hold one million people's stem cells. Beike will provide the initial investment of 30 million yuan. The base will include an R&D institute, stem cell engineering R&D center, stem cell bank and clinical application. Beike has built a stem cell application network by transferring technology to biomedical collaborators that provide patients with personalized therapy. The income generated will be shared with the partners. This innovative business model does not focus on drug discovery, thus reducing the investment risk and time frame of more than 10 years associated with traditional therapeutics. (Click here for more - Chinese Language)
You may also be interested in...
The national bioindustry base's stem cell industrialization project recently commenced construction in Taizhou, China's medical city in Jiangsu province. Projects to be built include centers for stem cell technology transfer, testing and clinical application services as well as Phase II of the Jiangsu stem cell bank. The bank can house one million specimens and is set to be Asia's largest stem cell bank upon completion (PharmAsia News, March 23, 2008). The commercialized base will be a comprehensive facility integrating stem cell storage, application and technology transfer. ShenZhen BeiKe Bio-Tech is investing in the base through its wholly-owned subsidiary Jiangsu Beike. The firm has collaborations with 30 local healthcare institutions on clinical research including optic nerve hypoplasia, progressive myodystrophy, cerebral palsy, paraplegia and myocardial infarction. (Click here for more - Chinese language)
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.